Health Care · Biological Products, (No Diagnostic Substances)

LENZ LENZ Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 181577662 filings
Russell 2000

LENZ at a glance

LENZ Therapeutics, Inc. (LENZ, SEC CIK 1815776) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), LENZ Therapeutics, Inc. (LENZ) reported revenue of $19.1 million and a net loss of $82.1 million. Diluted EPS was -$2.85.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding LENZ Therapeutics, Inc. (LENZ) shares worth $34.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on October 29, 2026 of 451,998 shares at $3.36 per share.
  • In the last 90 days, LENZ insiders reported 0 open-market purchases ($0) and 3 open-market sales ($9.1M) on Form 4, a net sale of $9.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$19.1M
10-K XBRL
Insiders · 90 days
0 buys · 3 sells
Net −$9.1M
13F holders
26 funds
$34.3M · +1 vs prior quarter
Latest 8-K
Oct 28, 2026
Item 2.02 · Item 2.05 · Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $15.1M, versus $12.5M license revenue YoY, with $2.6M product sales
  • Net loss $31.0M vs $16.7M YoY, with SG&A $35.8M vs $27.6M
  • VIZZ product sales best-performing line: $2.6M from approximately 38,000 packs
  • Cash, equivalents and marketable securities $197.3M; operating cash outflow $94.6M through nine months
  • Strategic reorganization: approximately 75% headcount reduction, approximately $5M restructuring charges expected in fourth quarter 2026

Risk Factors

  • New regulatory risk triggered by current administration: FDA staffing reductions and government shutdowns could delay reviews, inspections, and future approvals
  • Most material commercial update: October 2026 reorganization prioritizing consumer marketing and reducing operating expenses
  • Competitive risk: Ryzumvi approval in October 2026 adds another presbyopia treatment competitor
  • Market-acceptance risk: VIZZ remains vulnerable to patient concerns about prescription burden and side effects versus reading glasses
  • Financial risk: Net losses reached $104.4 million for nine months ended September 30, 2026, with accumulated deficit of $331.5 million

AI summary of the LENZ 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 28, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces LENZ’s financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed earnings figures and management commentary

Item 2.05: Costs Associated with Exit or Disposal Activities

  • Strategic reorganization prioritizes consumer marketing and sales-growth capital allocation
  • Headcount reduced approximately 75%, leaving approximately 40 full-time employees

Item EX-99.1: Item EX-99.1

  • Q3 product sales $2.6M, up 50% sequentially, with 38,000 paid prescriptions, supporting accelerating VIZZ adoption
  • Telehealth generated over 50% of incremental prescriptions, expanding access beyond traditional eye-care channels

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO Evert Schimmelpennink departs December 1, 2026, resigning from the Board; transition is stated as non-disputed
  • CFO Daniel Chevallard becomes Interim President and CEO while retaining CFO, principal financial and accounting officer responsibilities
Filed Aug 11, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces LENZ Therapeutics’ financial results for the quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed quarterly results and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 revenue $5.5M, including $1.7M product sales and $3.8M license revenue
  • VIZZ volume reached approximately 27,000 packs, up 9% sequentially, supporting early commercial traction
Filed Jul 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Zach Scheiner resigned from the Board and all committees effective June 30, 2026
  • Resignation unrelated to disputes over company operations, policies, or practices

AI summaries of LENZ 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LENZ

Don't miss the next LENZ filing

  • Alerts as it files. A push when LENZ files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LENZ, by share count.
  • Ask anything. An AI agent that reads every LENZ filing and answers with sources.

LENZ alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Chevallard Daniel R.AOct 30, 2026-
RA CAPITAL MANAGEMENT, L.P.SellOct 29, 2026$3.36
RA CAPITAL MANAGEMENT, L.P.SellOct 29, 2026$3.36
RA CAPITAL MANAGEMENT, L.P.SellOct 29, 2026$3.36
Guerard FredericAJun 15, 2026-
George Jeffrey P.AJun 15, 2026-
Thunen Shelley BAJun 15, 2026-
Drapkin Kimberlee CAJun 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$19.1M
Operating Income-$135.2M-$58.6M-$91.1M
Net Income-$124.7M-$49.8M-$82.1M
Op. Margin---477.5%
Net Margin---430.3%
Balance Sheet
Total Assets$188.5M$215.3M$305.9M
Equity-$204.1M$284.3M
ROE--24.4%-28.9%
Per Share
EPS-$-2.34$-2.85
Cash Flow
Operating CF-$90.0M-$59.4M-$69.2M
CapEx-$468K$827K

Source: XBRL data in LENZ Therapeutics, Inc. (LENZ)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LENZ share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LENZ shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$34.3M
Q2 202625$64.9M
Q1 202625$105.7M
Q4 202521$166.7M
Q3 202522$282.9M
Q2 202518$131.6M
Q1 202518$54.9M
Q4 202414$57.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LENZ filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 3, 2026Analysis
4Nov 3, 2026--
4Nov 2, 2026--
8-KOct 28, 2026Analysis-
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
8-KJul 2, 2026Analysis-
SC 13GJun 26, 2026-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 12, 2026Analysis-
8-KMay 11, 2026Analysis
10-QMay 11, 2026Analysis
SC 13GApr 27, 2026-
SC 13GApr 8, 2026-
4Mar 30, 2026--
4Mar 30, 2026--
4Mar 30, 2026--
8-KMar 24, 2026--
10-KMar 24, 2026-

Related Health Care companies

All Health Care →

LENZ SEC filings: frequently asked questions

Are LENZ insiders buying or selling?

In the last 90 days, LENZ Therapeutics, Inc. (LENZ) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $9.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LENZ stock?

As of September 30, 2026, the largest LENZ Therapeutics, Inc. (LENZ) holders among the 13F filers tracked by SignalX were BlackRock ($13.2 million), Millennium Management ($4.5 million), Vanguard Capital Management LLC ($4.2 million), Two Sigma Investments ($2.7 million), State Street Corp ($1.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LENZ's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), LENZ Therapeutics, Inc. (LENZ) reported revenue of $19.1 million and a net loss of $82.1 million. Diluted EPS was -$2.85. The figures come from the XBRL data in the 10-K.

What did LENZ report in its latest 8-K?

LENZ Therapeutics, Inc. (LENZ) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Press release announces LENZ’s financial results for the quarter ended September 30, 2026.

What are the latest LENZ SEC filings?

LENZ Therapeutics, Inc. (LENZ) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on November 3, 2026.

What is LENZ's SEC CIK number?

LENZ Therapeutics, Inc. (LENZ)'s SEC Central Index Key (CIK) is 1815776. EDGAR lists every LENZ filing under that number.

Ask anything about LENZ

The research agent reads LENZ's filings, financials, insider trades and 13F holders, then answers with sources.